SG Americas Securities LLC Purchases 6,774 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

SG Americas Securities LLC increased its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 43.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 22,498 shares of the company’s stock after buying an additional 6,774 shares during the period. SG Americas Securities LLC’s holdings in Harmony Biosciences were worth $774,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Harmony Biosciences by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock worth $80,000 after buying an additional 360 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares during the last quarter. CWM LLC boosted its holdings in shares of Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after purchasing an additional 775 shares during the last quarter. Mendota Financial Group LLC boosted its holdings in shares of Harmony Biosciences by 24,125.0% during the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after purchasing an additional 965 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in shares of Harmony Biosciences by 0.7% during the 2nd quarter. AQR Capital Management LLC now owns 154,345 shares of the company’s stock valued at $4,657,000 after purchasing an additional 1,116 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Analyst Ratings Changes

HRMY has been the subject of several research reports. Raymond James reissued an “outperform” rating and set a $40.00 price objective on shares of Harmony Biosciences in a report on Thursday, October 10th. Cantor Fitzgerald increased their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Oppenheimer reissued an “outperform” rating and set a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Needham & Company LLC restated a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a research report on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Harmony Biosciences in a research report on Monday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences currently has a consensus rating of “Buy” and a consensus price target of $55.00.

Insider Buying and Selling

In other news, insider Jeffrey Dierks sold 1,123 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total transaction of $44,920.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Sandip Kapadia sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total transaction of $1,004,500.00. The disclosure for this sale can be found here. Insiders have sold 72,452 shares of company stock valued at $2,831,679 in the last ninety days. 30.80% of the stock is owned by company insiders.

Harmony Biosciences Stock Performance

Harmony Biosciences stock opened at $38.82 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences Holdings, Inc. has a 1-year low of $28.14 and a 1-year high of $41.61. The firm has a market capitalization of $2.21 billion, a P/E ratio of 18.40, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78. The company’s 50-day moving average is $35.20 and its 200 day moving average is $35.22.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. During the same period in the prior year, the company posted $0.63 EPS. The firm’s revenue for the quarter was up 16.0% on a year-over-year basis. Research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.